S&P 500   3,982.21 (+0.28%)
DOW   32,464.49 (+0.70%)
QQQ   308.16 (-0.88%)
AAPL   158.31 (-1.21%)
MSFT   276.05 (-1.61%)
META   201.49 (-2.19%)
GOOGL   102.27 (-3.01%)
AMZN   97.34 (-0.81%)
TSLA   192.27 (+0.98%)
NVDA   264.11 (-1.37%)
NIO   8.93 (-1.54%)
BABA   85.82 (-1.24%)
AMD   95.95 (-2.04%)
T   18.83 (+1.18%)
F   11.52 (+0.09%)
MU   59.53 (-2.67%)
CGC   1.89 (-0.62%)
GE   92.81 (+1.58%)
DIS   94.64 (+0.60%)
AMC   4.33 (-3.13%)
PYPL   73.48 (-0.54%)
PFE   40.30 (-0.22%)
NFLX   328.58 (+0.06%)
S&P 500   3,982.21 (+0.28%)
DOW   32,464.49 (+0.70%)
QQQ   308.16 (-0.88%)
AAPL   158.31 (-1.21%)
MSFT   276.05 (-1.61%)
META   201.49 (-2.19%)
GOOGL   102.27 (-3.01%)
AMZN   97.34 (-0.81%)
TSLA   192.27 (+0.98%)
NVDA   264.11 (-1.37%)
NIO   8.93 (-1.54%)
BABA   85.82 (-1.24%)
AMD   95.95 (-2.04%)
T   18.83 (+1.18%)
F   11.52 (+0.09%)
MU   59.53 (-2.67%)
CGC   1.89 (-0.62%)
GE   92.81 (+1.58%)
DIS   94.64 (+0.60%)
AMC   4.33 (-3.13%)
PYPL   73.48 (-0.54%)
PFE   40.30 (-0.22%)
NFLX   328.58 (+0.06%)
S&P 500   3,982.21 (+0.28%)
DOW   32,464.49 (+0.70%)
QQQ   308.16 (-0.88%)
AAPL   158.31 (-1.21%)
MSFT   276.05 (-1.61%)
META   201.49 (-2.19%)
GOOGL   102.27 (-3.01%)
AMZN   97.34 (-0.81%)
TSLA   192.27 (+0.98%)
NVDA   264.11 (-1.37%)
NIO   8.93 (-1.54%)
BABA   85.82 (-1.24%)
AMD   95.95 (-2.04%)
T   18.83 (+1.18%)
F   11.52 (+0.09%)
MU   59.53 (-2.67%)
CGC   1.89 (-0.62%)
GE   92.81 (+1.58%)
DIS   94.64 (+0.60%)
AMC   4.33 (-3.13%)
PYPL   73.48 (-0.54%)
PFE   40.30 (-0.22%)
NFLX   328.58 (+0.06%)
S&P 500   3,982.21 (+0.28%)
DOW   32,464.49 (+0.70%)
QQQ   308.16 (-0.88%)
AAPL   158.31 (-1.21%)
MSFT   276.05 (-1.61%)
META   201.49 (-2.19%)
GOOGL   102.27 (-3.01%)
AMZN   97.34 (-0.81%)
TSLA   192.27 (+0.98%)
NVDA   264.11 (-1.37%)
NIO   8.93 (-1.54%)
BABA   85.82 (-1.24%)
AMD   95.95 (-2.04%)
T   18.83 (+1.18%)
F   11.52 (+0.09%)
MU   59.53 (-2.67%)
CGC   1.89 (-0.62%)
GE   92.81 (+1.58%)
DIS   94.64 (+0.60%)
AMC   4.33 (-3.13%)
PYPL   73.48 (-0.54%)
PFE   40.30 (-0.22%)
NFLX   328.58 (+0.06%)

USANA Health Sciences - USNA Stock Forecast, Price & News

$62.22
+0.86 (+1.40%)
(As of 03/27/2023 11:56 AM ET)
Add
Compare
Today's Range
$61.62
$62.22
50-Day Range
$55.44
$63.48
52-Week Range
$48.61
$83.78
Volume
9,884 shs
Average Volume
73,850 shs
Market Capitalization
$1.20 billion
P/E Ratio
17.33
Dividend Yield
N/A
Price Target
$52.75

USANA Health Sciences MarketRank™ Forecast

Analyst Rating
Hold
1.50 Rating Score
Upside/​Downside
14.4% Downside
$52.75 Price Target
Short Interest
Healthy
3.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$1.49 M Sold Last Quarter
Proj. Earnings Growth
15.09%
From $2.85 to $3.28 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

Medical Sector

579th out of 995 stocks

Medicinals & Botanicals Industry

4th out of 11 stocks


USNA stock logo

About USANA Health Sciences (NYSE:USNA) Stock

USANA Health Sciences, Inc. develops and manufactures nutritional, personal care and weight-management products. It operates under the following segments: USANA Nutritionals, USANA Foods, Personal Care and Skincare, and All Other. The firm's brands include Procosa and MagneCal D. The company was founded by Myron W. Wentz in September 1992 and is headquartered in Salt Lake City, UT.

Receive USNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for USANA Health Sciences and its competitors with MarketBeat's FREE daily newsletter.

USNA Stock News Headlines

Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
USANA Executive Director Takes Home Utah Award
USANA Health Sciences Announces CEO Transition Plan
Usana names new CEO
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
USANA Health Sciences Bottom Line Falls In Q4, but beats estimates
The Day the Music Died Celebrates Music, Brings Harmony
USANA Acquires Two Companies—Rise Bar & Oola
USANA Named Top Manufacturer in Utah
See More Headlines
Receive USNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for USANA Health Sciences and its competitors with MarketBeat's FREE daily newsletter.

USNA Company Calendar

Last Earnings
2/07/2023
Today
3/27/2023
Next Earnings (Estimated)
4/25/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
Personal Products
Sector
Medical
CUSIP
90328M10
Employees
1,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$52.75
High Stock Price Forecast
$53.00
Low Stock Price Forecast
$52.50
Forecasted Upside/Downside
-14.0%
Consensus Rating
Hold
Rating Score (0-4)
1.50
Research Coverage
2 Analysts

Profitability

Net Income
$69.35 million
Pretax Margin
10.88%

Debt

Sales & Book Value

Annual Sales
$998.60 million
Cash Flow
$4.79 per share
Book Value
$22.62 per share

Miscellaneous

Free Float
19,225,000
Market Cap
$1.18 billion
Optionable
Optionable
Beta
0.74

Key Executives

  • Kevin G. Guest
    Chairman & Chief Executive Officer
  • Jim BrownJim Brown
    President
  • Walter NootWalter Noot
    Chief Operating Officer
  • G. Douglas Hekking
    Chief Financial Officer
  • Robert Andrew SinnottRobert Andrew Sinnott
    Chief Scientific Officer













USNA Stock - Frequently Asked Questions

Should I buy or sell USANA Health Sciences stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" USNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in USNA, but not buy additional shares or sell existing shares.
View USNA analyst ratings
or view top-rated stocks.

What is USANA Health Sciences' stock price forecast for 2023?

2 analysts have issued 1-year price objectives for USANA Health Sciences' shares. Their USNA share price forecasts range from $52.50 to $53.00. On average, they expect the company's share price to reach $52.75 in the next twelve months. This suggests that the stock has a possible downside of 14.0%.
View analysts price targets for USNA
or view top-rated stocks among Wall Street analysts.

How have USNA shares performed in 2023?

USANA Health Sciences' stock was trading at $53.20 at the beginning of the year. Since then, USNA shares have increased by 15.3% and is now trading at $61.36.
View the best growth stocks for 2023 here
.

When is USANA Health Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 25th 2023.
View our USNA earnings forecast
.

How were USANA Health Sciences' earnings last quarter?

USANA Health Sciences, Inc. (NYSE:USNA) issued its earnings results on Tuesday, February, 7th. The company reported $0.66 EPS for the quarter, beating analysts' consensus estimates of $0.35 by $0.31. The company had revenue of $227.96 million for the quarter. USANA Health Sciences had a trailing twelve-month return on equity of 16.92% and a net margin of 6.94%. During the same quarter in the prior year, the business posted $1.03 EPS.

What guidance has USANA Health Sciences issued on next quarter's earnings?

USANA Health Sciences issued an update on its FY 2023 earnings guidance on Friday, February, 24th. The company provided EPS guidance of $2.35-$3.30 for the period, compared to the consensus earnings per share estimate of $3.35. The company issued revenue guidance of $850.00 million-$950.00 million, compared to the consensus revenue estimate of $959.85 million.

What is Kevin Guest's approval rating as USANA Health Sciences' CEO?

68 employees have rated USANA Health Sciences Chief Executive Officer Kevin Guest on Glassdoor.com. Kevin Guest has an approval rating of 99% among the company's employees. This puts Kevin Guest in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of USANA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include International Business Machines (IBM), Gilead Sciences (GILD), NVIDIA (NVDA), AT&T (T), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Walt Disney (DIS), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

What is USANA Health Sciences' stock symbol?

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

Who are USANA Health Sciences' major shareholders?

USANA Health Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (6.38%), Pzena Investment Management LLC (3.73%), Dimensional Fund Advisors LP (2.87%), Geode Capital Management LLC (1.18%), Charles Schwab Investment Management Inc. (0.99%) and Morgan Stanley (0.99%). Insiders that own company stock include Brent Neidig, Daniel A Macuga, Daniel A Macuga, David Mulham Mulham, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Gilbert A Fuller, Jim Brown, John Turman Fleming, Joshua Foukas, Kevin Guest, Myron W Wentz, Paul A Jones, Robert A Sinnott, Robert Auciaux, Timothy E Wood and Walter Noot.
View institutional ownership trends
.

How do I buy shares of USANA Health Sciences?

Shares of USNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is USANA Health Sciences' stock price today?

One share of USNA stock can currently be purchased for approximately $61.36.

How much money does USANA Health Sciences make?

USANA Health Sciences (NYSE:USNA) has a market capitalization of $1.18 billion and generates $998.60 million in revenue each year. The company earns $69.35 million in net income (profit) each year or $3.59 on an earnings per share basis.

How many employees does USANA Health Sciences have?

The company employs 1,900 workers across the globe.

How can I contact USANA Health Sciences?

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The official website for the company is www.usana.com. The company can be reached via phone at (801) 954-7100, via email at investor.relations@usanainc.com, or via fax at 801-954-7300.

This page (NYSE:USNA) was last updated on 3/27/2023 by MarketBeat.com Staff